Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma-Reference-Cited by-同舟云学术

Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma

Published:2020-09-29 Issue:11 Volume:20 Page:957-963
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

de Sande González Luis Miguel¹,Martin-Broto Javier²,Kasper Bernd³,Blay Jean-Yves⁴⁵^ORCID,Le Cesne Axel⁶

Affiliation:

1. Medical Oncology Department, Leon University Hospital, León, Spain

2. MUsculoSkeletal Tumor Board of Excellence Sevilla (MUSTBE SEVILLA), Virgen del Rocío University Hospital, Sevilla, Spain

3. Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, University Medical Center, University of Heidelberg, Theodor‑Kutzer‑Ufer, Mannheim, Germany

4. Medical Oncology Department, Centre Léon Bérard, Lyon, France

5. Medical Oncology Department, Université Claude Bernard Lyon I, Lyon, France

6. Medical Oncology Department, Gustave Roussy, Villejuif, France

Funder

PharmaMar

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2020.1822744

Reference39 articles.

1. European Medicine Agency. Yondelis. European public assessment report. [cited 2020 sep 21]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis

2. Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

3. Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy

4. Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients

5. Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress on the role of tumor‑associated macrophages in tumor development and their use as molecular targets (Review);International Journal of Oncology;2023-12-07

2. Trabectedin use in soft‐tissue sarcoma patients in a real‐world setting: Data from an Italian national drug‐access registry;International Journal of Cancer;2022-10-13

3. Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential;Cancer Letters;2022-10

4. A review of the efficacy of trabectedin as second-line treatment of advanced soft tissue sarcoma;Future Oncology;2022-09

5. The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety data;Future Oncology;2022-09